DDInter906 DDInter1628
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Ifosfamide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is regulated by {v} (Gene) ZNF263
ZNF263 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is regulated by {v} (Gene) LTK
LTK {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Ifosfamide {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) regulates {v} (Gene) TBPL1
TBPL1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ifosfamide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Ifosfamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Ifosfamide (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Ruxolitinib (Compound)
Ifosfamide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Ifosfamide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Ifosfamide (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is regulated by ZNF263 (Gene) and ZNF263 (Gene) is upregulated by Ruxolitinib (Compound)
Ifosfamide (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is regulated by LTK (Gene) and LTK (Gene) is bound by Ruxolitinib (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Ifosfamide (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) regulates TBPL1 (Gene) and TBPL1 (Gene) is upregulated by Ruxolitinib (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)